Atoms, the innovative footwear brand redefining the concept of everyday shoes, has successfully raised an impressive $100 million in its latest funding round. Founded with a singular vision, Atoms embodies simplicity and function, offering just one shoe design that caters to all aspects of life—from work to leisure and everything in between. This funding will enable the company to expand its operations, enhance its production capabilities, and further develop its unique offerings, including the pioneering feature of providing sneakers in 1/4 sizes, ensuring a perfect fit for every individual. By honing in on one versatile design, Atoms eliminates the overwhelming choices often faced by consumers, promoting a more mindful approach to footwear. The capital raised will not only drive product innovation and sustainability efforts but also allow Atoms to strengthen its brand presence in the competitive sneaker market. With this round of funding, the company is dedicated to refining its manufacturing processes and potentially exploring environmentally friendly materials, further enhancing the overall customer experience. As Atoms continues to champion the mantra of "one for your everyday," it remains committed to making quality, versatile footwear accessible to everyone, transforming the way we think about and wear our sneakers. This significant financial backing marks a pivotal step in Atoms' journey, sealing its status as a game changer in the footwear industry.
Breaking News: Atoms Secures $100M in Series C Funding to Revolutionize Everyday Footwear
Get the full Atoms company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Anveshan
We are a food-tech startup aiming to provide high quality deeply traceable food products. We leverage technologies based on image processing, spectroscopy, blockchain and IOT to provide the best quality food products made traditionally.
$12.7M Series b
today
Caseway
We are the only enterprise AI form platform that replaces internal R&D and manual workflows by building and maintaining fully integrated automation systems, aligned to your data, your processes, and your long-term success. For document-intensive, compliance-driven organizations in regulated industries like insurance, education, finance, healthcare, and government Compelling reason to buy: Who need AI and automation tailored to their unique forms, workflows, and security environment, without having to shoulder R&D risk or manage AI development internally Product category: Our product is an enterprise document form platform Key benefit: That delivers a fully integrated, continuously improving automation system, built and maintained by experts, without upfront AI build costs Key differentiation: Our product is custom-built for each client’s systems and documents, fully integrated and continuously improved through a long-term partnership model, we maintain, debug, adapt, and align incentives to make it work in the real world.
$1.5M Pre-seed
today
Kubera Health
Kubera’s mission is to power a payment ecosystem where contracts are honored, care is rewarded, and waste is eliminated. We deliver contract and payment intelligence that unifies policies, terms, and claims data into one trusted platform — helping healthcare organizations and their partners build fairer contracts, ensure payments flow as intended, and align incentives across the care ecosystem. As healthcare shifts toward new reimbursement models and risk-sharing arrangements, Kubera is building the payment-intelligence backbone that enables multiple parties to adapt faster, protect margins, and dedicate more resources to patient care.
$6.5M Seed
today
Psilera
Psilera is a biotechnology company founded by scientists dedicated to finding better therapeutics for neurological conditions like dementia, addiction, and mental health disorders. Since 2019, Psilera has been focused on early-stage drug discovery & development with a dynamic team of experts in synthetic chemistry, pharmacology, clinical development, and business development.
$8.8M Seed
today
Abstract
Abstract is a venture capital firm based in San Francisco with $1.5 billion in assets under management. We are sector-agnostic, focused on seed and early stage founders. Our reputation among founders is built on fierce loyalty, unparalleled connections, and a relentless drive to help them win.
$59.0M Series a
today
Other recent Series c rounds
Companies that recently closed a Series c round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Daloopa United States | Series c | $47.0M | today |
| 2 |  WeRoad Italy | Series c | $58.0M | 1d ago |
| 3 |  Trellis Bioscience Inc. United States | Series c | $6.1M | 1d ago |
| 4 |  Modal United States | Series c | $355.0M | 3d ago |
| 5 |  Cardless United States | Series c | $50.0M | 5d ago |